Erschienen in:
01.01.2005 | Adis R&D Profile
Histrelin Hydrogel Implant — Valera
Histrelin Implant, LHRH-Hydrogel Implant, RL 0903, SPD 424
Erschienen in:
Drugs in R&D
|
Ausgabe 1/2005
Einloggen, um Zugang zu erhalten
Excerpt
Valera Pharmaceuticals, formerly Hydro Med Sciences, is developing a once-yearly Histrelin Hydrogel Implant [Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424, Vantas™], a subcutaneous (SC) reservoir device capable of long-term delivery of histrelin at constant release rates for the treatment of prostate cancer. Histrelin is a luteinising hormone-releasing hormone agonist (LHRH). A different formulation of the LHRH implant is currently in development for the treatment of central precocious puberty (CPP). …